Back to top

Syndax targets expanded $10B market opportunity with Revuforj and Niktimvo amid accelerating adoption and guidance for stable expenses

Syndax targets expanded $10B market opportunity with Revuforj and Niktimvo amid accelerating adoption and guidance for stable expenses

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Syndax Pharmaceuticals, Inc. (SNDX)